REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPSMarket Beat·Aug 6 at 10:56 PMRGNX-2.29%
REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% UpsideTradingView·Aug 6 at 06:20 PMRGNX-2.29%
Regenxbio Q2 FY26 swings to net income of $22.71 million; revenue climbs to $108.02 millionPUBT·Aug 6 at 06:21 AMRGNX-2.29%ABBV+3.43%
Regenxbio | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 108.02 MEarnings Watch·Aug 6 at 06:16 AMRGNX-2.29%
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from AnalystsMarket Beat·Aug 4 at 01:29 AMRGNX-2.29%
Regenxbio schedules conference call to discuss second-quarter results and operational updatePUBT·Aug 3 at 06:05 AMRGNX-2.29%
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights | RGNX Stock NewsStockTitan·Aug 2 at 10:05 PMRGNX-2.29%
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmPR Newswire·Jul 21 at 06:29 PMRGNX-2.29%
